IP Library › Granted Patent US 12,337,199

Granted Patent B2

US 12,337,199 · App. 17/155,432 · Granted Jun 24, 2025

Stable antibody formulation

Inventors: Yuan Cao (White Plains, NY); Dingjiang Liu (Pleasantville, NY); Long Xu (Shanghai, CN)

Assignee: REGENERON PHARMACEUTICALS, INC.

A61K39/39591 A61K39/42 A61K47/22 A61K47/26 A61P31/12

View Patent ↗

Loading inventors, assignments & file history…

Monitor This Case

Get email alerts when status or documents change.

Order Certified Copies

Most orders are placed with the USPTO same day — all within 24 business hours.

Order via The Patent Place →

Pre-filled with this patent's details

Quick Facts

Patent No.: US 12,337,199
App. No.: 17/155,432
Granted: Jun 24, 2025
Kind: B2

External Links

USPTO Patent Center↗ Full Patent PDF↗

Abstract

The present disclosure provides stable pharmaceutical formulations comprising a human antibody that specifically binds to Ebola Virus (EBOV). In certain embodiments, the formulations contain, in addition to an anti-EBOV antibody, a buffer, an amino acid, a non-ionic surfactant, and a stabilizer. The pharmaceutical formulations of the present disclosure exhibit a substantial degree of antibody stability upon stress, for example, agitation during transport, and storage, for example, storage at temperatures greater than 40° C.

Claims (224)

1. A stable liquid pharmaceutical formulation comprising:

(a) sucrose at a concentration from 10%±2% to 20%±4% w/v;

(b) a buffer comprising histidine at a concentration from 5 mM±1 mM to 20 mM±4 mM;

(d) at least one antibody which binds specifically to Ebola virus (EBOV) and comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained in a heavy chain variable region/light chain variable region (HCVR/LCVR) amino acid sequence pair selected from the group consisting of (i) SEQ ID NOs: 2/10, (ii) SEQ ID NOs: 20/28, and (iii) SEQ ID NOs: 38/46;

wherein the formulation comprises the following: (i), (ii), (iii), (i)+(ii), (i)+(iii), (ii)+(iii), or (i)+(ii)+(iii), at a total antibody concentration from 5 mg/mL±0.75 mg/mL to 250 mg/mL±37.5 mg/mL; and

wherein the formulation has a pH of 6.0±0.3; and

wherein the formulation maintains ADCC potency of at least about 90% in an ADCC bioassay and/or demonstrates that at least 90% of the antibody is the native species after storage at a temperature from about 40° C. to about 45° C. for no less than 20 days.

2. The pharmaceutical formulation of claim 1 , wherein the total antibody concentration is 50 mg/mL±7.5 mg/mL.

3. The pharmaceutical formulation of claim 1 , wherein the total antibody concentration is 100 mg/mL±15.0 mg/mL.

4. The pharmaceutical formulation of claim 1 , wherein the polysorbate is polysorbate 80.

5. The pharmaceutical formulation of claim 1 , comprising:

(a) from 10%±2% to 15%±3% w/v sucrose,

(b) from 5 mM±1 mM to 20 mM±4 mM histidine buffer,

(d) (i)+(ii)+(iii) in an amount of 50 mg/mL±7.5 mg/mL total antibody,

at pH 6.0±0.3.

6. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 50 mg/mL±7.5 mg/mL total antibody,

at pH 6.0±0.3;

wherein the antibody comprises three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained in the HCVR/LCVR amino acid sequence pair of (i) SEQ ID NOs: 2/10.

7. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 50 mg/mL±7.5 mg/mL total antibody,

at pH 6.0±0.3;

8. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 50 mg/mL±7.5 mg/mL total antibody,

at pH 6.0±0.3;

9. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 50 mg/mL±7.5 mg/mL total antibody,

at pH 6.0±0.3;

10. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 50 mg/mL±7.5 mg/mL total antibody,

at pH 6.0±0.3;

11. The pharmaceutical formulation of claim 1 comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 50 mg/mL±7.5 mg/mL total antibody,

at pH 6.0±0.3;

12. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 50 mg/mL±7.5 mg/mL total antibody,

at pH 6.0±0.3;

wherein a first antibody comprises three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained in the HCVR/LCVR amino acid sequence pair of (i) SEQ ID NOs: 2/10, a second antibody comprises three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained in the HCVR/LCVR amino acid sequence pair of (ii) SEQ ID NOs: 20/28, and a third antibody comprises three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained in the HCVR/LCVR amino acid sequence pair of (iii) SEQ ID NOs: 38/46.

13. The pharmaceutical formulation of claim 1 , comprising:

(a) from 10%±2% to 15%±3% w/v sucrose,

(b) from 5 mM±1 mM to 20 mM±4 mM histidine buffer,

(d) (i)+(ii)+(iii) in an amount of 100 mg/mL±15 mg/mL total antibody,

at pH 6.0±0.3.

14. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 100 mg/mL±15 mg/mL total antibody,

at pH 6.0±0.3;

15. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 100 mg/mL±15 mg/mL total antibody,

at pH 6.0±0.3;

16. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 100 mg/mL±15 mg/mL total antibody,

at pH 6.0±0.3;

17. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 100 mg/mL±15 mg/mL total antibody,

at pH 6.0±0.3;

18. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 100 mg/mL±15 mg/mL total antibody,

at pH 6.0±0.3;

19. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 100 mg/mL±15 mg/mL total antibody,

at pH 6.0±0.3;

20. The pharmaceutical formulation of claim 1 , comprising:

(a) 10%±2% w/v sucrose,

(b) 10 mM±2 mM histidine buffer,

(d) 100 mg/mL±15 mg/mL total antibody,

at pH 6.0±0.3;

21. The pharmaceutical formulation of claim 1 comprising:

(a) a combination of three antibodies that bind specifically to EBOV, wherein the three antibodies comprise a heavy chain variable region/light chain variable region (HCVR/LCVR) amino acid sequence pair of (i) SEQ ID NOs: 2/10, (ii) SEQ ID NOs: 20/28, and (iii) SEQ ID NOs: 38/46, respectively, and wherein the total antibody concentration is 50 mg/mL±7.5 mg/mL,

(b) 10 mM±2 mM histidine buffer, pH 6.0±0.3,

(d) 10%±2% w/v sucrose; wherein:

(i) at least 96% of the antibody is the native species after 12 months at 5° C.;

(ii) at least 97% of the antibody is the native species after 120 minutes agitation; and

(iii) at least 97% of the antibody is the native species after 8 freeze thaw cycles.

22. The pharmaceutical formulation of claim 1 comprising:

(b) 10 mM±2 mM histidine buffer, pH 6.0±0.3,

(d) 10%±2% w/v sucrose; wherein:

(i) at least 96% of the antibody is the native species after 12 months at 5° C.;

(ii) at least 97% of the antibody is the native species after 120 minutes agitation; and

(iii) at least 97% of the antibody is the native species after 8 freeze thaw cycles.

23. The pharmaceutical formulation of claim 1 , wherein the antibody comprises an HCDR1 of SEQ ID NO: 4, an HCDR2 of SEQ ID NO: 6, an HCDR3 of SEQ ID NO: 8, an LCDR1 of SEQ ID NO: 12, an LCDR2 of SEQ ID NO: 14, and an LCDR3 of SEQ ID NO: 16.

24. The pharmaceutical formulation of claim 1 , wherein the antibody comprises an HCVR of SEQ ID NO: 2 and an LCVR of SEQ ID NO: 10.

25. The pharmaceutical formulation of claim 1 , wherein the antibody comprises an HCDR1 of SEQ ID NO: 22, an HCDR2 of SEQ ID NO: 24, an HCDR3 of SEQ ID NO: 26, an LCDR1 of SEQ ID NO: 30, an LCDR2 of SEQ ID NO: 32, and an LCDR3 of SEQ ID NO: 34.

26. The pharmaceutical formulation of claim 1 , wherein the antibody comprises an HCVR of SEQ ID NO: 20 and an LCVR of SEQ ID NO: 28.

27. The pharmaceutical formulation of claim 1 , wherein the antibody comprises an HCDR1 of SEQ ID NO: 40, an HCDR2 of SEQ ID NO: 42, an HCDR3 of SEQ ID NO: 44, an LCDR1 of SEQ ID NO: 48, an LCDR2 of SEQ ID NO: 50, and an LCDR3 of SEQ ID NO: 52.

28. The pharmaceutical formulation of claim 1 , wherein the antibody comprises an HCVR of SEQ ID NO: 38 and an LCVR of SEQ ID NO: 46.

29. A kit comprising the pharmaceutical formulation of claim 1 , a container, and instructions.

30. The kit of claim 29 , wherein the container is a glass vial.

31. The kit of claim 29 , wherein the container is a prefilled syringe.

32. The kit of claim 29 , wherein the container is an autoinjector.

33. The pharmaceutical formulation of claim 1 , wherein the antibodies or antigen-binding fragments thereof of (i)+(ii)+(iii) are present in a ratio of 1:1:1.

34. The pharmaceutical formulation of claim 1 , formulated for intravenous administration, intramuscular administration, subcutaneous administration, intraperitoneal administration, percutaneous administration, mucosal administration, nasal administration, pulmonary administration, or oral administration.

35. A stable liquid pharmaceutical formulation comprising:

(a) sucrose at a concentration of 10%±2% w/v;

(b) a buffer comprising histidine at a concentration less than 10 mM±2 mM;

(d) a first antibody comprising three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained in the HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 2/10;

a second antibody comprising three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained in the HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 20/28, and

a third antibody comprising three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) and three light chain CDRs (LCDR1, LCDR2 and LCDR3) contained in the HCVR/LCVR amino acid sequence pair of SEQ ID NOs: 38/46,

wherein the concentration of each of the first antibody, the second antibody and the third antibody in the formulation is from 10 mg/ml±0.75 mg/mL to 40 mg/ml±7.5 mg/mL;

wherein the formulation has a pH of 6.0±0.3; and

36. The pharmaceutical formulation of claim 35 , wherein the concentration of each of the first antibody, the second antibody and the third antibody is 16.67 mg/mL±1.25 mg/ml.

37. The pharmaceutical formulation of claim 35 , wherein the concentration of each of the first antibody, the second antibody and the third antibody is 33.33 mg/mL±2.5 mg/ml.

38. The pharmaceutical formulation of claim 35 , further comprising L-histidine monohydrochloride monohydrate at a concentration of no more than 25 mM±5 mM.

39. The pharmaceutical formulation of claim 35 , wherein the first antibody comprises an HCDR1 of SEQ ID NO: 4, an HCDR2 of SEQ ID NO: 6, an HCDR3 of SEQ ID NO: 8, an LCDR1 of SEQ ID NO: 12, an LCDR2 of SEQ ID NO: 14, and an LCDR3 of SEQ ID NO: 16.

40. The pharmaceutical formulation of claim 39 , wherein the first antibody comprises an HCVR of SEQ ID NO: 2 and an LCVR of SEQ ID NO: 10.

41. The pharmaceutical formulation of claim 40 , wherein the first antibody comprises a heavy chain of SEQ ID NO: 17 and a light chain of SEQ ID NO: 18.

42. The pharmaceutical formulation of claim 35 , wherein the second antibody comprises an HCDR1 of SEQ ID NO: 22, an HCDR2 of SEQ ID NO: 24, an HCDR3 of SEQ ID NO: 26, an LCDR1 of SEQ ID NO: 30, an LCDR2 of SEQ ID NO: 32, and an LCDR3 of SEQ ID NO: 34.

43. The pharmaceutical formulation of claim 42 , wherein the second antibody comprises an HCVR of SEQ ID NO: 20 and an LCVR of SEQ ID NO: 28.

44. The pharmaceutical formulation of claim 43 , wherein the second antibody comprises a heavy chain of SEQ ID NO: 35 and a light chain of SEQ ID NO: 36.

45. The pharmaceutical formulation of claim 35 , wherein the third antibody comprises an HCDR1 of SEQ ID NO: 40, an HCDR2 of SEQ ID NO: 42, an HCDR3 of SEQ ID NO: 44, an LCDR1 of SEQ ID NO: 48, an LCDR2 of SEQ ID NO: 50, and an LCDR3 of SEQ ID NO: 52.

46. The pharmaceutical formulation of claim 45 , wherein the third antibody comprises an HCVR of SEQ ID NO: 38 and an LCVR of SEQ ID NO: 46.

47. The pharmaceutical formulation of claim 46 , wherein the third antibody comprises a heavy chain of SEQ ID NO: 53 and a light chain of SEQ ID NO: 54.

48. The pharmaceutical formulation of claim 35 , wherein said formulation is contained in a container.

49. The pharmaceutical formulation of claim 48 , wherein the container is a vial and the total volume of the pharmaceutical formulation contained in each vial is 14.5 mL±0.5 mL.

50. The pharmaceutical formulation of claim 49 , wherein the pharmaceutical formulation contained in each vial comprises 0.74 mg/mL±0.05 mg/mL of L-histidine, 1.09 mg/mL±0.05 mg/mL of L-histidine monohydrochloride monohydrate, 1 mg/mL±0.05 mg/mL of polysorbate 80, 100 mg/mL±5 mg/mL of sucrose and water.

51. The pharmaceutical formulation of claim 35 , formulated for intravenous administration.

52. The pharmaceutical formulation of claim 35 , wherein the first antibody, the second antibody and the third antibody in the formulation are at a 1:1:1 ratio and the final dose of the three antibodies to be administered is 150 mg/kg±15 mg/kg of body weight.

53. The pharmaceutical formulation of claim 51 , wherein the formulation is diluted in a PVC intravenous (IV) bag containing 0.9% Sodium Chloride, 5% Dextrose or Lactated Ringer's prior to the intravenous administration.

54. The pharmaceutical formulation of claim 53 , wherein the final concentration of each of the first antibody, the second antibody and the third antibody after dilution is between about 2 mg/mL to about 30 mg/mL.

55. The pharmaceutical formulation of claim 53 , wherein the duration of the intravenous administration of the diluted formulation is between about 2 hours to about 4 hours.

56. A stable liquid pharmaceutical formulation at a volume of 14.5 mL comprising:

(a) 16.67 mg/mL of a first antibody comprising an HCDR1 of SEQ ID NO: 4, an HCDR2 of SEQ ID NO: 6, an HCDR3 of SEQ ID NO: 8, an LCDR1 of SEQ ID NO: 12, an LCDR2 of SEQ ID NO: 14, and an LCDR3 of SEQ ID NO: 16,

(b) 16.67 mg/mL of a second antibody comprising an HCDR1 of SEQ ID NO: 22, an HCDR2 of SEQ ID NO: 24, an HCDR3 of SEQ ID NO: 26, an LCDR1 of SEQ ID NO: 30, an LCDR2 of SEQ ID NO: 32, and an LCDR3 of SEQ ID NO: 34, and

(c) 16.67 mg/mL of a third antibody comprising an HCDR1 of SEQ ID NO: 40, an HCDR2 of SEQ ID NO: 42, an HCDR3 of SEQ ID NO: 44, an LCDR1 of SEQ ID NO: 48, an LCDR2 of SEQ ID NO: 50, and an LCDR3 of SEQ ID NO: 52,

(d) sucrose at a concentration of 10%±2% w/v,

(e) a buffer comprising histidine at a concentration less than 10 mM±2 mM,

(f) an organic cosolvent comprising polysorbate at a concentration less than 0.2%±0.1% w/v,

57. The stable liquid pharmaceutical formulation of claim 56 , wherein

the first antibody comprises an HCVR of SEQ ID NO: 2 and an LCVR of SEQ ID NO: 10,

the second antibody comprises an HCVR of SEQ ID NO: 20 and an LCVR of SEQ ID NO: 28,

and the third antibody comprises an HCVR of SEQ ID NO: 38 and an LCVR of SEQ ID NO: 46.

58. The stable liquid pharmaceutical formulation of claim 56 , wherein the first antibody comprises a heavy chain of SEQ ID NO: 17 and a light chain of SEQ ID NO: 18,

the second antibody comprises a heavy chain of SEQ ID NO: 35 and a light chain of SEQ ID NO: 36; and

the third antibody comprises a heavy chain of SEQ ID NO: 53 and a light chain of SEQ ID NO: 54.

59. The stable liquid pharmaceutical formulation of claim 56 comprising:

0.74 mg/mL of L-histidine,

1.09 mg/mL of L-histidine monohydrochloride monohydrate,

1 mg/mL of polysorbate 80,

100 mg/mL of sucrose, and

water;

wherein the formulation has a pH of 6.0.

60. A stable liquid pharmaceutical formulation at a volume of 14.5 mL comprising:

(a) 33.33 mg/mL of a first antibody comprising an HCDR1 of SEQ ID NO: 4, an HCDR2 of SEQ ID NO: 6, an HCDR3 of SEQ ID NO: 8, an LCDR1 of SEQ ID NO: 12, an LCDR2 of SEQ ID NO: 14, and an LCDR3 of SEQ ID NO: 16,

(b) 33.33 mg/mL of a second antibody comprising an HCDR1 of SEQ ID NO: 22, an HCDR2 of SEQ ID NO: 24, an HCDR3 of SEQ ID NO: 26, an LCDR1 of SEQ ID NO: 30, an LCDR2 of SEQ ID NO: 32, and an LCDR3 of SEQ ID NO: 34, and

(c) 33.33 mg/mL of a third antibody comprising an HCDR1 of SEQ ID NO: 40, an HCDR2 of SEQ ID NO: 42, an HCDR3 of SEQ ID NO: 44, an LCDR1 of SEQ ID NO: 48, an LCDR2 of SEQ ID NO: 50, and an LCDR3 of SEQ ID NO: 52,

(d) sucrose at a concentration of 10%±2% w/v,

(e) a buffer comprising histidine at a concentration less than 10 mM±2 mM,

(f) an organic cosolvent comprising polysorbate at a concentration less than 0.2%±0.1% w/v,

61. The stable liquid pharmaceutical formulation of claim 60 , wherein

the first antibody comprises an HCVR of SEQ ID NO: 2 and an LCVR of SEQ ID NO: 10;

the second antibody comprises an HCVR of SEQ ID NO: 20 and an LCVR of SEQ ID NO: 28,

and the third antibody comprises an HCVR of SEQ ID NO: 38 and an LCVR of SEQ ID NO: 46.

62. The stable liquid pharmaceutical formulation of claim 60 , wherein

the first antibody comprises a heavy chain of SEQ ID NO: 17 and a light chain of SEQ ID NO: 18;

the second antibody comprises a heavy chain of SEQ ID NO: 35 and a light chain of SEQ ID NO: 36; and

the third antibody comprises a heavy chain of SEQ ID NO: 53 and a light chain of SEQ ID NO: 54.

63. The stable liquid pharmaceutical formulation of claim 60 , comprising:

0.74 mg/mL of L-histidine,

1.09 mg/mL of L-histidine monohydrochloride monohydrate,

1 mg/mL of polysorbate 80,

100 mg/mL of sucrose, and

water;

wherein the formulation has a pH of 6.0.

Assignments (1)

ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 16, 2022

From: CAO, YUAN; LIU, DINGJIANG; XU, LONG

To: REGENERON PHARMACEUTICALS, INC.

Reel/Frame 060229/0849 →

Continuity (2)

Provisional Application 62965786 · Jan 24, 2020

Related Publication 20210252146A1 · Aug 19, 2021

References Cited (51)

US 4997423A · Okuda et al. · 1991 [cited by applicant]

US 5908686A · Sudo et al. · 1999 [cited by applicant]

US 6286699B1 · Sudo · 2001 [cited by applicant]

US 6629949B1 · Douglas · 2003 [cited by applicant]

US 6630144B1 · Hart et al. · 2003 [cited by applicant]

US 6645635B2 · Muraki · 2003 [cited by applicant]

US 6659982B2 · Douglas et al. · 2003 [cited by applicant]

US 6875433B2 · Hart et al. · 2005 [cited by applicant]

US 7226554B2 · Sudo et al. · 2007 [cited by applicant]

US 7335356B2 · Hart et al. · 2008 [cited by applicant]

US 8513391B2 · Jones et al. · 2013 [cited by applicant]

US 9771414B2 · Kyratsous · 2017 [cited by examiner]

US 10081670B2 · Kyratsous · 2018 [cited by examiner]

US 10501526B2 · Kyratsous · 2019 [cited by examiner]

US 10829544B2 · Kyratsous · 2020 [cited by examiner]

US 11530255B2 · Kyratsous · 2022 [cited by examiner]

US 20090232795A1 · Condra · 2009 [cited by examiner]

US 20160215040A1 · Kyratsous et al. · 2016 [cited by applicant]

US 20160304607A1 · Sadineni et al. · 2016 [cited by applicant]

EP 1539238 · 2007 [cited by applicant]

WO WO2010048615 · 2010 [cited by applicant]

WO WO2012135408A1 · 2012 [cited by applicant]

WO WO2014031718A1 · 2014 [cited by applicant]

WO WO2016123019 · 2016 [cited by applicant]

WO WO2018204405A1 · 2018 [cited by applicant]

WO WO2019206987A1 · 2019 [cited by applicant]

Rudikoff et al, Proc Natl Acad Sci USA 1982 vol. 79 p. 1979-1983. [cited by examiner]

Bolton, et al. (2011) “Effect of Protein and Solution Properties on the Donnan Effect During the Ultrafiltration of Proteins”, Biotechnol. Prog. 27(1):140-152. [cited by applicant]

Cao, et al. (2019) “Charge Variants Characterization and Release Assay Development for Co-Formulated Antibodies as a Combination Therapy”, mAbs 11(3):489-499. [cited by applicant]

European Medicines Agency (2008) “Guideline on the Non-Clinical Development of Fixed Combination Medicinal Productions” Version 1:1-6. [cited by applicant]

European Medicines Agency (2017) “Guideline on Clinical Development of Fixed Combination Medicinal Products” Revision 2:1-12. [cited by applicant]

FDA (2018) “Combination Product Definition Combination Product Types” https://www.fda.gov/combination-products/about-combination-products/combination-product-definition-combination-product-types#:˜:text=Any%20investigat… [cited by applicant]

Glover et al., (2013) “Compatibility and Stability of Pertuzumab and Trastuzumab Admixtures in i.v. Infusion Bags for Coadministration”, J Pharm Sci., 102(3):794-812. [cited by applicant]

Henricks, et al. (2015) “The use of Combinations of Monoclonal Antibodies in Clinical Oncology”, Cancer Treatment Reviews, 41:859-867. [cited by applicant]

Karali “Fixed Dose Combination (FDC) Products Overview” PharmaCircle LLC https://www.pharmacircle.com/presentations/Fixed_Dose.pdf. [cited by applicant]

Kirschbrown, et al. (2019) “Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study”, The Journal of Clinical Pharmacology, 59(5):702-716. [cited by applicant]

Meehan, et al. (1997) “A Microinfusor Device for the Delivery of Therapeutic Levels of Peptides and Macromolecules”, J. Controlled Release, 46:107-116. [cited by applicant]

Mueller et al. (2018) “Challenges for the Pharmaceutical Technical Development of Protein Coforumulations”, Journal of Pharmacy and Pharmacology, 70: 666-674. [cited by applicant]

Patel, et al. (2018) “Coformulation of Broadly Neutralizing Antibodies 3BNC117 and PGT121: Analytical Challenges During Preformulation Characterization and Storage Stability Studies”, Journal of Pharmaceutical Sciences,… [cited by applicant]

Robinson (2002) “Protein Deamidation”, PNAS, 99(8):5283-5288. [cited by applicant]

Shpilberg & Jackisch (2013) “Subcutaneous Administration of Rituximab (MabThera) and Trastuzumab (Herceptin) Using Hualuronidase”, British Journal of Cancer, 109:1556-1561. [cited by applicant]

Svitel (2019) “Analytical Strategies for Fixed-Dose Coformulated Protein Therapeutics”, BioProcess International. [cited by applicant]

U.S. Department of Health and Human Services (2013) “Guideline for Industry: Codevelopment of Two or More New Investigational Drugs for Use in Combinations” 1-13. [cited by applicant]

Wang, et al. (2007) “Antibody Structure, Instability, and Formulation”, J. Pharma. Sci. 96: 1-26. [cited by applicant]

Who Drug Information (2003) “Regulatory Challenges” 17(3):174-177. [cited by applicant]

Woldeyes, et al. (2018) “Viscosities and Protein Interactions of Bispecific Antibodies and Their Monospecific Mixtures”, Molecular Pharmaceutics, 15:4745-4755. [cited by applicant]

Baek, et al. (2016) “Effects of Histidine and Sucrose on the Biophysical Properties of a Monoclonal Antibody”, Pharm. Res., 34:629-639. [cited by applicant]

Falconer (2019) “Advances in Liquid Formulations of Parenteral Therapeutic Proteins”, Biotechnology Advances 37 (7):107412, 9pages. [cited by applicant]

International Search Report and Written Opinion received in PCT/US2021/014524 on May 12, 2021 (16 pages). [cited by applicant]

Kang, et al. (2016) “Rapid Formulation Development for Monoclonal Antibodies”, Internet Link URL: http://www.bioprocessintl.com/manufacturing/formulation/rapid-formulation-development-for-monoclonal-antibodies/. [cited by applicant]

Dondelinger et al. (2018) “Understanding the Significance and Implications of Antibody Numbering and AntigenBinding Surface/Residue Definition”, Frontiers in Immunology, 9(2278): 1-15. [cited by applicant]

Cited By (1)

US 12,514,939